AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02492763
Drug: MK-8521
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.
Trial: NCT02492763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
Trial: NCT01394003
Drug: LY2584702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT00716417
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
Trial: NCT00716417
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low to high dose, daily
Trial: NCT02298582
Drug: intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
Trial: NCT02885025
Drug: normal saline nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline to replace nasal fluticasone in specific arms of the study
Trial: NCT04343248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily for six weeks
Trial: NCT01320982
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: minocycline 100 mg/bid
Trial: NCT01320982
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid 500mg/ bid
Trial: NCT01320982
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo bid
Trial: NCT00461370
Drug: SRX251
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03968562
Drug: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
Trial: NCT03774576
Drug: RO7017773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of RO7017773
Trial: NCT01746901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution + Placebo ALO-02 (intact)
Trial: NCT01746901
Drug: intact ALO-02 60 mg/7.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution + ALO-02 60 mg/7.2 mg (intact)
Trial: NCT01746901
Drug: crushed ALO-02 60 mg/7.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
Trial: NCT01746901
Drug: crushed ALO-02 40 mg/4.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
Trial: NCT04341870
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
Trial: NCT00790842
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
Trial: NCT04225897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle administered orally
Trial: NCT00664625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Once Daily, Single Dose
Trial: NCT03622489
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mentioned above
Trial: NCT03622489
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mentioned above
Trial: NCT04668456
Drug: bupivacine 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subtenon injection
Trial: NCT04668456
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: either subtenon or iv
Trial: NCT02863419
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once-daily.
Trial: NCT01208207
Drug: Part I - etoricoxib 60 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 mg oral tablet once daily for 6 weeks
Trial: NCT01208207
Drug: Part I - etoricoxib 90 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg oral tablet once daily for 6 weeks
Trial: NCT01208207
Drug: Part I- naproxen 1000 mg
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg oral tablet twice daily for 6 weeks
Trial: NCT01208207
Drug: Part I - Placebo to naproxen 500 mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
Trial: NCT01208207
Drug: Part II- etoricoxib 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 mg oral tablet once daily for 20 weeks
Trial: NCT01208207
Drug: Part II- etoricoxib 90 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg oral tablet once daily for 20 weeks
Trial: NCT01208207
Drug: Part II- naproxen 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg oral tablet twice daily for 20 weeks
Trial: NCT01208207
Drug: Part I - Placebo to etoricoxib 60 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
Trial: NCT01208207
Drug: Part I - Placebo to etoricoxib 90 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
Trial: NCT01208207
Drug: Part II- Placebo to etoricoxib 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
Trial: NCT01208207
Drug: Part II - Placebo to etoricoxib 90 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
Trial: NCT01208207
Drug: Part II- Placebo to naproxen 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to naproxen 500 mg orally twice daily for 20 weeks.
Trial: NCT00548340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, PO daily for five weeks
Trial: NCT03112603
Drug: Extracorporeal photopheresis (ECP)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
Trial: NCT03112603
Drug: Low-dose methotrexate (MTX)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT01411124
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00156624
Drug: Balloon Angioplasty with or without drug administration
RxNorm normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04480359
Drug: Bawei Shenqi Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.1g, once a day, 3month, oral
Trial: NCT04480359
Drug: Bawei Shenqi Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.1g, once a day, 3month, oral
Trial: NCT00043979
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3.
Trial: NCT00043979
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
Trial: NCT04480359
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5mg, once a day, 3 month, oral
Trial: NCT03367988
Drug: Opioid Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Trial: NCT03367988
Drug: Opioid-free Anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Trial: NCT02192489
Drug: CC-220 0.3 mg Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192489
Drug: CC-220 0.6mg Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00203099
Drug: Glatiramer Acetate, N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
Trial: NCT01755182
Drug: approved pharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03566134
Drug: DA-8010 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive placebo to match DA-8010 orally once a day.
Trial: NCT03566134
Drug: DA-8010 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive DA-8010 2.5mg orally once a day.
Trial: NCT04198558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03891108
Drug: BMS-986231 Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
Trial: NCT03891108
Drug: BMS-986231 Formulation D
RxNorm normalized name: Rho(D) - Unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
Trial: NCT01397214
Drug: Megace F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megace F oral suspension
Trial: NCT02919995
Drug: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPL554 suspension administered using a nebuliser
Trial: NCT02919995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution administered using a nebuliser
Trial: NCT01860066
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 via inhaler twice a day
Trial: NCT02849899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
Trial: NCT02902289
Drug: Ibuprofen 200 mg/5 mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02902289
Drug: MOMENT 200 mg coated tablet
RxNorm normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02094924
Drug: GSK587323
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of FDC tablet formulation to be taken orally.
Trial: NCT00988728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner.
Trial: NCT01190462
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02403648
Drug: BIOD-961
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIOD-961 is a lyophilized glucagon formulation.
Trial: NCT00531544
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU011248 Expanded Access Protocol for Systemic Therapy
Trial: NCT00926718
Drug: remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
Trial: NCT00926718
Drug: rocuronium dose + remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
Trial: NCT00926718
Drug: rocuronium dose + remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
Trial: NCT00926718
Drug: remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
Trial: NCT00926718
Drug: rocuronium dose + remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
Trial: NCT00926718
Drug: rocuronium dose + remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
Trial: NCT02015312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Trial: NCT00209612
Drug: Campt, Topotesin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1,15 Y mg/m2, IV (in the vein)
Trial: NCT03410693
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
Trial: NCT00826202
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg/day
Trial: NCT02750917
Drug: Lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
Trial: NCT02750917
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
Trial: NCT02368860
Drug: oxaliplatin, irinotecan, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
Trial: NCT01680042
Drug: Phenytoin paste
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01680042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00953576
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02855788
Drug: Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metronomic chemotherapy
Trial: NCT01340846
Drug: GSK2118436 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2118436 dosed at 150mg twice daily
Trial: NCT01340846
Drug: GSK2118436 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2118436 dosed at 75mg twice daily
Trial: NCT03714958
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT04398927
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
Trial: NCT01323101
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
Trial: NCT03714672
Drug: Tramadol/Diclofenac 50/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Trial: NCT03714672
Drug: Tramadol/Diclofenac 25/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Trial: NCT03714672
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Trial: NCT03692299
Drug: Saccharomyces Boulardii Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
Trial: NCT01399372
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
Trial: NCT02724618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Trial: NCT01421719
Drug: Cystoscopic injection of Botox into the urinary bladder
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.